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plantation. We performed a retrospective analysis of 70 patients;
20 prior to the institution of Kepivance(palifermin), and 50 pa-
tients after. The preparative regimens include Melphalan, Busulfan
& Etoposide, Cytoxan, BCNU, Etoposide, and Busulfan & Cy-
toxan.
The average length of stay for non-Kepivance patients was 32.3
days compared to 28 days in patients who received the drug. The
severity of both oral and GI mucositis appeared to be less. 85% of
non-Kepivance patients experienced diarrhea or rectal irritation,
versus 52% with Kepivance. Neutropenic fever was noted in 95%
of patients that did not receive the drug and 76% of the patients
that did. There was a trend torward earlier engraftment in the
Kepivance group.
Kepivance seems to have had a positive effect on our patients.
This updated study suggests an improvement in mucositis symp-
toms with the use of Kepivance(palifermin). It appears that mu-
cositis and its treatment contribute to the length of stay and costs
of stem cell transplantation. Qualtiy of life for these patients can be
greatly improved if mucositis is reduced during the course of stem
cell transplantation.
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ROLE OF HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM
CELL TRANSPLANTATION IN PRIMARY SYSTEMIC AMYLOIDOSIS: A
SYSTEMATIC REVIEW
Behera, M.1, Kharfan-Dabaja, M.A.1, Kumar, A.1, Soares, H.P.1,
Djulbegovic, B.1 1H. Lee Mofﬁtt Cancer Center and Research Institute at
the University of South Florida, Tampa, FL.
Background: Primary systemic amyloidosis (AL) is a rare plasma
cell clonal disorder(8/million) characterized by extracellular depos-
its of material composed mainly of fragments of light chain immu-
noglobulin throughout a body. Standard chemotherapy (e.g. mel-
phalan and prednisone) is associated with poor outcomes (typical
median survival is between 12-18 months with less than 5% sur-
viving 10 years). Autologous stem cell transplant (ASCT) has been
increasingly advocated for the treatment of AL. However, it is
uncertain whether ASCT is better than standard chemotherapy.
To address this uncertainty, we undertook a systematic review/
meta-analysis to evaluate the efﬁcacy of high-dose chemotherapy
and autologous stem-cell transplant (HSCT) versus conventional
chemotherapy in patients with AL.
Methods: We searched for all published studies in Medline and
Cochrane library databases. In addition, we hand searched for
references. Studies were included if they were comparison trials of
HSCT versus conventional chemotherapy, regardless of the trial
design (e.g. randomized controlled trials [RCTs] or prospective
studies with historical control). The studies were eligible if patients
had biopsy proven AL with at least one major organ involved .Data
were extracted on beneﬁts as well as harms (overall survival, event-
free survival, response, treatment related mortality, treatment-
related morbidity).
Results: Out of 34 identiﬁed studies only 4 met the inclusion
criteria for the current systematic review, two of which were RCTs
and two were prospective non-randomized trials that included histor-
ical control. The ages of patients were in the range of 18-69 years.
When we pooled all the data, we found that overall survival was
similar for ASCT and conventional therapy arms [hazard ratio (HR)
of 1.10 (95% CI 0.88, 1.36, p0.4); no signiﬁcant heterogeneity was
found; p 0.6]. Analysis of data according to design (randomized vs.
non-randomized trials) resulted in similar results [HR1.10 (95% CI
0.88, 1.37) and HR0.98 (95% CI 0.29, 3.35), respectively]. The
complete hematologic response was also similar between the 2 arms
[OR 1.38 (95% CI 0.67, 2.85; p0.4].
Conclusion: The results from the meta-analysis indicate that
there is no statistically signiﬁcant difference between the treatment
effects from high-dose chemotherapy with ASCT and conven-
tional chemotherapy. Hence, the efﬁcacy of ASCT in improving
overall survival and complete hematologic response remains to be
proven.
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DOSE DENSE DREIFACH* MELPHALAN100 FOR MULTIPLE MYELOMA
Berz, D.1, McCormack, E.2, Winer, E.2, Karwan, P.2, Colvin, G.2,
Rathore, R.2, Larry, L.2, Elfenbein, G.2, Quesenberry, P.2 1Brown
University, Providence, RI; 2Roger Williams Medical Center, Provi-
dence, RI.
Background: Tandem high dose melphalan therapy with autolo-
gous peripheral stem cell support has emerged as standard of care for
patients without prohibitive comorbidities. Mucositis and gastrointes-
tinal side effects are the most common extrahematologic side effects.
Two previously published studies presented a triple transplant with a
conditioning regimen melphalan 100mg/m2 (MEL100) with periph-
eral stem cell support every two to ﬁve months schedule for patients
with prohibitive comorbidities for high dose tandem transplantation.
We are presenting a novel approach that investigates the triple mel-
phalan100/m2 approach on a dose dense, every three weeks schedule
in a patient population without signiﬁcant comorbidities.
Patients andmethods:Thirteen standard or high risk patients with
stageIII multiple myeloma were prospectively treated. This popula-
tion contained eight patients with IgG clonality, 3 IgA, 1 nonsecretory
and one light chain isotype. The induction regimens of the thirteen
patients were heterogenous and included 5 VAD, 3 DCIE, 2 Thal/
Dex, 2 CIE and 1 pulse decadron. Patients underwent peripheral
blood leukopheresis, and these cells were divided into three equal sets
and frozen. The patients were scheduled to receive Melphalan at
100mg/m2 on day -1, 20, and 41 and then the autologous infusions
occurred at day 0, 21, and 42.
Results: All patients were able to receive all three cycles of the
MEL100 regimen. Seven patients (54%) received the treatments on
the every three week schedule; three treatments (23%) during the
second cycle and six treatments (46%) of the third cycle had to be
delayed a median of 6 and 4 days respectively. Three patients were
managed completely in the outpatient setting, and the average total
hospital stay for the three transplants was 18 days.Median progression
free survival was 854 days (range 73 – 1571) and the overall survival of
this cohort has yet to be reached. No patient had worse than grade II
mucositis, and no serious adverse events were recorded.
Conclusions:Our regimen of three consecutive autologous periph-
eral stem cell transplants with a reduced dose of melphalan at
100mg/m2 given every three weeks is very well tolerated. The pro-
gression free survival and overall survival are similar and can be
compared favorably with the standard tandem myeloma regimens.
Our data is intriguing and further studies with larger numbers need to
be performed to conﬁrm these results. *German for triple.
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OUTCOMES ASSOCIATED WITH AGE IN PATIENTS WITH MALIGNANT
LYMPHOMA RECEIVING AUTOLOGOUS STEM CELL TRANSPLANT
Beveridge, C.A.1, Ershler, W.B.2, Orloff, G.J.1, Sheridan, M.J.3,
Shelton, M.V.1 1Fairfax Northern Virginia Hematology-Oncology, PC,
Fairfax, VA; 2Institute for Advanced Studies in Aging, Washington,
DC; 3Inova Fairfax Hospital, Falls Church, VA.
Background and Rationale
Older age is frequently considered a contraindication to high
dose therapy. We evaluated 32 auto-transplant patients with Ma-
lignant Lymphoma (ML) to determine whether outcomes for those
60 years of age differed from those 60 years of age.
Material and Methods
A retrospective assessment was undertaken of ML patients who
were transplanted at Inova Fairfax Hospital from 2004-2006. All
patients had Karnofsky performance scores of 80% and all were
apheresed using a high volume technique and ideal body weight for
calculations with either G-CSF (G) or GGM-CSF, with a goal of
5106/kg CD34 cells. Patients were treated with growth factor sup-
port using GM-CSF beginning day 4 through ANC recovery of
1000. Blood product replacement was standardized to transfuse for
hemoglobin greater than 8gm/dl or platelet counts of10,000/mm3.
Viability was performed using ﬂow cytometry and propidium iodide.
Continuous variables were analyzed as means and 95% conﬁdence
intervals, but p-values were produced using a Wilcoxon Rank Sum
Test for non-normally distributed data. Categorical variables were
analyzed using a Fisher’s Exact Test.
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